Story
Ipsen Shares Fall After FDA Approves Generic Version of Key Cancer Drug Somatuline
Summary
Shares in the French drugmaker fell nearly 7% after U.S. regulators approved Amneal Pharmaceuticals' generic rival to Somatuline, a treatment that accounts for about 30% of Ipsen's revenue.
Shares of French pharmaceutical company Ipsen (IPN) fell nearly 7% in Monday trading following the U.S. Food and Drug Administration's approval of a generic competitor to its top-selling drug, Somatuline. Amneal Pharmaceuticals announced it would launch its generic version immediately, introducing significant competition for one of Ipsen's primary revenue sources.
FDA Greenlights Generic Rival
The FDA on Friday approved Amneal's lanreotide injection (120 mg/0.5 mL), a generic equivalent to Ipsen's Somatuline Depot, according to a statement from the New Jersey-based drugmaker. The product, which is supplied in a pre-filled syringe, received a Competitive Generic Therapy designation from the agency.
Lanreotide is a crucial treatment for several conditions, including the hormonal disorder acromegaly and certain types of tumors, such as advanced gastroenteropancreatic neuroendocrine tumors and carcinoid syndrome.
AdImpact on Ipsen's Revenue
The market reaction reflects the strategic importance of Somatuline to Ipsen's financial performance. The drug is a blockbuster product for the company, generating approximately 30% of its total revenue in the first half of 2026.
The introduction of a lower-priced generic alternative is expected to erode the market share and pricing power of the brand-name drug. According to data from IQVIA, U.S. sales for Somatuline totaled $983 million for the 12-month period ending in July 2026, highlighting the substantial market that Amneal is now positioned to enter.
Read next
More on Stocks
AMD Stock Rallies Sharply, But High Valuation and Technicals Signal Consolidation Risk
Advanced Micro Devices shares surged over 9% on Monday, supported by strong revenue forecasts tied to AI growth. However, an Investing.com analysis indicates that overbought technical signals and a high valuation could increase the risk of a near-term pullback or sideways trading.
Fertilizer Stocks Fall After Trump Signals Potential US-Belarus Potash Deal
Shares of major fertilizer producers including Mosaic and Nutrien declined sharply Monday following a social media post from President Trump indicating the U.S. is pursuing a deal to import lower-cost potash from Belarus.
Citi Projects 53% Surge in AI-Driven Enterprise SSD Demand by 2027, Recommends Samsung and SK Hynix
A new Citi report forecasts that artificial intelligence will drive a 52.9% year-over-year increase in enterprise solid-state drive (eSSD) demand in 2027, creating a significant supply deficit and benefiting key memory chip manufacturers.
S&P Cuts Telus Outlook to Stable on Weaker Guidance, Higher Leverage Forecast
S&P Global Ratings has revised its outlook on Telus Corp. to 'Stable' from 'Positive,' citing the company's weaker financial guidance which is expected to result in higher leverage. The rating agency affirmed the telecom's 'BBB-' credit rating.